1: Fortin A, Dorlo TP, Hendrickx S, Maes L. Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis. J Antimicrob Chemother. 2016 Jul;71(7):1892-8. doi: 10.1093/jac/dkw089. Epub 2016 Apr 15. PubMed PMID: 27084920.
2: Holtappels M, Swinnen E, De Groef L, Wuyts J, Moons L, Lagrou K, Van Dijck P, Kucharíková S. Antifungal Activity of Oleylphosphocholine on In Vitro and In Vivo Candida albicans Biofilms. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01767-17. doi: 10.1128/AAC.01767-17. Print 2018 Jan. PubMed PMID: 29061737; PubMed Central PMCID: PMC5740347.
3: Paulussen C, Boulet G, Bosschaerts T, Cos P, Fortin A, Maes L. Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis. Mycoses. 2015 Mar;58(3):127-32. doi: 10.1111/myc.12286. Epub 2015 Jan 15. PubMed PMID: 25590577.
4: Sonzogni-Desautels K, Renteria AE, Camargo FV, Di Lenardo TZ, Mikhail A, Arrowood MJ, Fortin A, Ndao M. Oleylphosphocholine (OlPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice. Front Microbiol. 2015 Sep 23;6:973. doi: 10.3389/fmicb.2015.00973. eCollection 2015. PubMed PMID: 26441906; PubMed Central PMCID: PMC4585137.
5: Hernández L, Gálvez R, Montoya A, Checa R, Bello A, Bosschaerts T, Jansen H, Rupérez C, Fortin A, Miró G. First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum. Parasitol Res. 2014 Jan;113(1):157-64. doi: 10.1007/s00436-013-3638-2. Epub 2013 Nov 6. PubMed PMID: 24192865.
6: Fortin A, Caridha DP, Leed S, Ngundam F, Sena J, Bosschaerts T, Parriott S, Hickman MR, Hudson TH, Grogl M. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis. PLoS Negl Trop Dis. 2014 Sep 11;8(9):e3144. doi: 10.1371/journal.pntd.0003144. eCollection 2014 Sep. PubMed PMID: 25210745; PubMed Central PMCID: PMC4161350.
7: Fortin A, Hendrickx S, Yardley V, Cos P, Jansen H, Maes L. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. J Antimicrob Chemother. 2012 Nov;67(11):2707-12. doi: 10.1093/jac/dks273. Epub 2012 Jul 10. PubMed PMID: 22782488.
8: Shio MT, Paquet M, Martel C, Bosschaerts T, Stienstra S, Olivier M, Fortin A. Drug delivery by tattooing to treat cutaneous leishmaniasis. Sci Rep. 2014 Feb 24;4:4156. doi: 10.1038/srep04156. PubMed PMID: 24561704; PubMed Central PMCID: PMC3932479.
9: Thaler A, Hottkowitz T, Eibl H. Separation and quantification of alkylphosphocholines by reversed phase high performance liquid chromatography. Chem Phys Lipids. 2000 Sep;107(1):131-9. PubMed PMID: 10974237.
10: Eibl KH, Banas B, Schoenfeld CL, May CA, Neubauer AS, Priglinger S, Kampik A, Welge-Lussen U. Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3556-61. PubMed PMID: 12882807.